Table 3.

Marketed PD-L1 antibodies.

Name (Trade name)	Company	First FDA approval	Medical uses	ORR		tr-AE (Grade ≥3) (%)
				PD-L1+ (%)	PD-L1– (%)
Atezolizumab (Tecentriq)	Roche Genetech	2016	Urothelial carcinoma, NSCLC	26	9.5	17
Avelumab (Bavencio)	Merck Serono and Pfizer	2017	Merkel-cell carcinoma	53.8	4.2	6.8
Durvalumab (Imfinzi)	AstraZeneca	2017	Urothelial carcinoma	31	0	4.9

ORR, objective responsive rate to solid tumor; AE, adverse event; tr-AE, treatment-related adverse event; NSCLC, non-small cell lung cancer.

Data source: highlights of prescribing information for Tecentriq, Bavencio, and Imfinzi. ORR and AE data refer to Apolo et al. (36), Massard et al. (37), McDermott et al. (38), Ning et al. (39).